Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2019-12-05
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incidence of Liver Disease-Related Outcomes in People With HIV
NCT06940375
Liver Diseases in PLWH
NCT04446156
Lifestyle Modification Programme for HIV-infected Individuals With Fatty Liver
NCT03913351
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
NCT04795219
Nonalcoholic Fatty Liver Disease in HIV Database
NCT05023044
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV-monoinfected outpatients
No intervention; cross-sectional study
No intervention; cross-sectional study
No intervention; cross-sectional study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention; cross-sectional study
No intervention; cross-sectional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV-positive patients;
* written the informed consent
Exclusion Criteria
* secondary causes of fatty liver (eg, consumption of amiodarone and tamoxifen) and decompensated liver disease;
* significant alcohol consumption (\>20 g per day for man, \>10 g per day for woman);
* received antibiotics in preceding two months;
* autoimmune disease;
* severe heart, lung, kidney, brain, blood diseases or other important systemic diseases;
* pregnant or lactating women
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Public Health Clinical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hongzhou Lu
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Xu W, Liu D, Zhang R, Chen J, Shen Y. Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction-Associated Steatotic Liver Disease. Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf369. doi: 10.1093/ofid/ofaf369. eCollection 2025 Jul.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20191126V2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.